Array Biopharma, Inc. (ARRY) Posts Q4 Loss of 9c/Share, Narrower than Views
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $7.39 +2.07%
Revenue Growth %: -12.3%
Financial Fact:
License and milestone revenue: 1.66M
Today's EPS Names:
DTGI, CRMT, STZ, More
Revenue Growth %: -12.3%
Financial Fact:
License and milestone revenue: 1.66M
Today's EPS Names:
DTGI, CRMT, STZ, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q4 EPS of ($0.09), $0.04 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $20.7 million versus the consensus estimate of $21.45 million.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Phinia to acquire stoba Group in deal expected to close in Q4 2026
- SportsMed Physical Therapy Named a 2026 Health Care Heroes Honoree
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
